FDA Fails to Routinely Test Drugs or Track Consumer Harm

---

Full Story

A ProPublica investigation revealed the FDA does not routinely test drugs circulating in the U.S. The agency also fails to proactively track consumer harm from these drugs. This raises concerns about pharmaceutical safety oversight. The findings highlight gaps in federal regulatory practices.

The FDA oversees drug approvals and safety for the U.S. market. Its lack of routine testing leaves potential risks unmonitored.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 38% | Right 26% | Center 31% | Unrated 5%

The Context

The investigation found no system for proactively tracking drug-related harm. Consumers may face undetected side effects or complications.

Drug safety relies on post-market reports from manufacturers and doctors. These reports often lag, delaying responses to issues.

The FDA’s budget and staffing constraints limit its monitoring capacity. This affects its ability to ensure drug safety nationwide.

Public trust in pharmaceuticals depends on robust federal oversight. The findings may erode confidence in the FDA’s effectiveness.

Some argue for increased FDA funding to improve testing. Others believe industry self-regulation could address oversight gaps.

The investigation calls for reforms to strengthen drug safety protocols. It may spur demands for greater FDA accountability.